Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/biomedicines9080864 http://scihub22266oqcxt.onion/10.3390/biomedicines9080864 34440068!8389559!34440068     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34440068&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Biomedicines 2021 ; 9 (8): ? Nephropedia Template TP {{tp|p=34440068|t=2021. What Do We Know about Thromboprophylaxis and Its Monitoring in Critically Ill Patients?|pdf=|usr=}}{{34440068}} gab.com Text What Do We Know about Thromboprophylaxis and Its Monitoring in Critically Ill Patients JO: Biomedicines http://www.kidney.de/pget.php?&tw=1&pmid=34440068 #FOAvip Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is an important complication in patients hospitalized in intensive care units (ICU). Thromboprophylaxis is mainly performed with Low Molecular Weight Heparin (LMWH) and, in some specific patients, with Unfractionated Heparin (UFH). These intensive units are an environment where individual patient variability is extreme and where traditional antithrombotic protocols are frequently ineffective. This was known for a long time, but the hospitalization of many patients with COVID-19 inflammatory storms suddenly highlighted this knowledge. It is therefore reasonable to propose variable antithrombotic prevention protocols based initially on a series of individual criteria (weight, BMI, and thrombotic risks). Secondly, they should be adjusted by the monitoring of anticoagulant activity, preferably by measuring the anti-Xa activity. However, we still face unresolved questions, such as once- or twice-daily LMWH injections, monitoring at the peak and/or trough, and poorly defined therapeutic targets. Equally surprisingly, we observed a lack of standardization of the anti-Xa activity kits. Twit Text FOAVip What Do We Know about Thromboprophylaxis and Its Monitoring in Critically Ill Patients ????Biomedicines http://www.kidney.de/pget.php?&tw=1&pmid=34440068 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34440068 #FOAvip English Wikipedia <ref>{{Cite pmid|34440068}}</ref> What Do We Know about Thromboprophylaxis and Its Monitoring in Critically Ill Patients? #MMPMID34440068 Cauchie P; Piagnerelli M Biomedicines 2021[Jul]; 9 (8): ? PMID34440068show ga Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is an important complication in patients hospitalized in intensive care units (ICU). Thromboprophylaxis is mainly performed with Low Molecular Weight Heparin (LMWH) and, in some specific patients, with Unfractionated Heparin (UFH). These intensive units are an environment where individual patient variability is extreme and where traditional antithrombotic protocols are frequently ineffective. This was known for a long time, but the hospitalization of many patients with COVID-19 inflammatory storms suddenly highlighted this knowledge. It is therefore reasonable to propose variable antithrombotic prevention protocols based initially on a series of individual criteria (weight, BMI, and thrombotic risks). Secondly, they should be adjusted by the monitoring of anticoagulant activity, preferably by measuring the anti-Xa activity. However, we still face unresolved questions, such as once- or twice-daily LMWH injections, monitoring at the peak and/or trough, and poorly defined therapeutic targets. Equally surprisingly, we observed a lack of standardization of the anti-Xa activity kits. ?What Do We Know about Thromboprophylaxis and Its Monitoring in Critica(epmc).pdf DeepDyve Pubget Overpricing